- Home
- CCTG vs AIM Comparison
CCTG vs AIM Comparison
Compare CCTG & AIM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CCTG
- AIM
- Stock Information
- Founded
- CCTG 1993
- AIM 1966
- Country
- CCTG Hong Kong
- AIM United States
- Employees
- CCTG N/A
- AIM N/A
- Industry
- CCTG
- AIM Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- CCTG
- AIM Health Care
- Exchange
- CCTG Nasdaq
- AIM Nasdaq
- Market Cap
- CCTG 18.1M
- AIM 15.9M
- IPO Year
- CCTG 2024
- AIM N/A
- Fundamental
- Price
- CCTG $1.50
- AIM $0.20
- Analyst Decision
- CCTG
- AIM Strong Buy
- Analyst Count
- CCTG 0
- AIM 2
- Target Price
- CCTG N/A
- AIM $2.75
- AVG Volume (30 Days)
- CCTG 19.5K
- AIM 403.8K
- Earning Date
- CCTG 07-22-2024
- AIM 11-15-2024
- Dividend Yield
- CCTG N/A
- AIM N/A
- EPS Growth
- CCTG N/A
- AIM N/A
- EPS
- CCTG N/A
- AIM N/A
- Revenue
- CCTG $14,748,551.00
- AIM $190,000.00
- Revenue This Year
- CCTG N/A
- AIM N/A
- Revenue Next Year
- CCTG N/A
- AIM $1,086.80
- P/E Ratio
- CCTG N/A
- AIM N/A
- Revenue Growth
- CCTG N/A
- AIM N/A
- 52 Week Low
- CCTG $1.20
- AIM $0.16
- 52 Week High
- CCTG $30.00
- AIM $0.62
- Technical
- Relative Strength Index (RSI)
- CCTG 35.47
- AIM 40.44
- Support Level
- CCTG $1.59
- AIM $0.20
- Resistance Level
- CCTG $1.69
- AIM $0.23
- Average True Range (ATR)
- CCTG 0.10
- AIM 0.02
- MACD
- CCTG -0.02
- AIM 0.00
- Stochastic Oscillator
- CCTG 0.00
- AIM 10.75
About CCTG CCSC Technology International Holdings Limited
CCSC Technology International Holdings Ltd along with its subsidiaries is involved in the sale, design, and manufacturing of interconnect products, including connectors, cables, and wire harnesses. Its products include customized interconnect products, including connectors, cables, and harnesses that are used for a range of applications in a diversified set of industries, including industrial, automotive, robotics, medical equipment, computer, network and telecommunication, and consumer products. Geographically, the company generates maximum revenue from the sale of its products in Europe and the rest from the Americas and Asia.
About AIM AIM ImmunoTech Inc.
AIM ImmunoTech Inc is an immuno-pharma company focused on research and development of therapeutics to treat immune disorders and viral and cancer diseases. AIM's flagship products include Ampligen (Rintatolimod), a drug of large macromolecular RNA molecules for cancer and viral diseases, and the drug Alferon N Injection for a category of STD infection. Clinical trials of Ampligen include studies of cancer patients with renal cell carcinoma, malignant melanoma, colorectal cancer, advanced recurrent ovarian cancer, and triple-negative metastatic breast cancer. It is also advancing Ampligen as a potential treatment for COVID-19. FDA has authorized the first human trial assessing the safety and effectiveness of Ampligen in combination with interferon alfa-2b, in cancer patients with COVID-19.